Search

Your search keyword '"Ganzel, Chezi"' showing total 384 results
Start Over Author "Ganzel, Chezi"
384 results on '"Ganzel, Chezi"'

1. Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Author

Altman, Jessica K., Zuckerman, Tsila, Koprivnikar, Jamie, McCloskey, James, Kota, Vamsi, Keng, Michael, Frankfurt, Olga, Abaza, Yasmin, Bixby, Dale L., Emadi, Ashkan, Burch, Micah, Bhatnagar, Bhavana, Luger, Selina M., Percival, Mary-Elizabeth, Wolach, Ofir, Craig, Michael, Ganzel, Chezi, Roboz, Gail, Levi, Itai, Gourevitch, Anna, Flaishon, Liat, Tessler, Shoshi, Blumberg, Chen, Gengrinovitch, Stela, Ben Yakar, Ruth, and Rowe, Jacob M.

Published
2023
Full Text
View/download PDF

4. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

Author

Ganzel, Chezi, Sun, Zhuoxin, Baslan, Timour, Zhang, Yanming, Gönen, Mithat, Abdel-Wahab, Omar I., Racevskis, Janis, Garrett-Bakelman, Francine, Lowe, Scott W., Fernandez, Hugo F., Ketterling, Rhett, Luger, Selina M., Litzow, Mark, Lazarus, Hillard M., Rowe, Jacob M., Tallman, Martin S., Levine, Ross L., and Paietta, Elisabeth

Published
2022
Full Text
View/download PDF

6. Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis.

Author

Bnaya, Alon, Ganzel, Chezi, and Shavit, Linda

Subjects
*IMMUNOGLOBULIN light chains, *BLOOD diseases, *ACUTE kidney failure, *NEPHROTIC syndrome, *RENAL biopsy
Abstract

Introduction: Monoclonal immunoglobulin deposition diseases (MIDDs) are a group of systemic diseases, characterized by deposition of monoclonal immunoglobulin predominantly in the kidney. In the absence of overt hematologic disease, MIDDs are classified as a part of monoclonal gammopathy of renal significance. Patients with MIDD may present with a nephrotic syndrome and kidney function impairment. Treatment usually includes anti-plasma cell therapy. Case Presentation: We report a case of a 54-year-old female who presented with nephrotic syndrome related to light chain deposition disease of lambda type. Due to a complicated clinical course (including cardiac injury and thromboembolic stroke), plasma cell-targeted therapy was stopped. A few months later, the patient presented with severe acute kidney injury. Kidney biopsy revealed crescentic glomerulonephritis, and immunofluorescence staining was positive for lambda chain. Treatment with daratumumab was initiated resulting in stabilization of kidney function and partial nephrotic syndrome remission. Conclusion: This case highlights an uncommon histologic manifestation in a patient diagnosed with light chain deposition disease. Furthermore, it underscores the significance of plasma cell-targeted therapy and the favorable clinical and hematological response observed with daratumumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia.

Author

Kugler, Eitan, Cohen, Inbar, Amitai, Irina, Ram, Ron, Frisch, Avraham, Nachmias, Boaz, Canaani, Jonathan, Moshe, Yakir, Krayem, Baher, Aumann, Shlomzion, Henig, Israel, Vainstein, Vladimir, Shargian, Liat, Ganzel, Chezi, Yeshurun, Moshe, Levi, Itay, Raanani, Pia, Akria, Luiza, Ofran, Yishai, and Shimony, Shai

Subjects
ACUTE myeloid leukemia, PROTEIN-tyrosine kinases, VENETOCLAX, OVERALL survival, HEMATOPOIETIC stem cell transplantation
Abstract

Summary: Patients with FLT3‐mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard‐of‐care for patients with R/R FLT3‐mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt‐ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib (n = 19) and gilt‐ven (n = 17) for R/R AML after intensive chemotherapy. Gilteritinib and gilt‐ven groups did not differ in terms of mCRc rates (53% and 65%, p = 0.51) and realization of allogeneic haematopoietic stem‐cell transplantation (HSCT, 47% and 35%, p = 0.5). Overall survival (OS) was comparable between groups, although a trend towards better OS was seen with gilt‐ven (12‐month OS 58.8% [95% CI 39.5%–87.6%]) versus gilteritinib (42.1% [95% CI 24.9%–71.3%] for gilteritinib). Early salvage with gilt‐ven versus any other gilteritinib‐based approach was associated with the best outcome (p = 0.031). Combination therapy was associated with increased haematological toxicity. In summary, gilt‐ven did not improve remissions or HSCT‐realization rates in patients with R/R FLT3‐mutated AML as compared with gilteritinib and was associated with increased haematological toxicity. Although OS did not differ, a trend towards better survival was suggested with gilt‐ven and a survival benefit was shown for gilt‐ven approach when sequenced early for salvage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Author

Cohen, Yael C., Zada, Mor, Wang, Shuang-Yin, Bornstein, Chamutal, David, Eyal, Moshe, Adi, Li, Baoguo, Shlomi-Loubaton, Shir, Gatt, Moshe E., Gur, Chamutal, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, and Pasvolsky, Oren

Subjects
Oncology, Experimental, Molecular dynamics -- Research, Drug resistance -- Research, Multiple myeloma -- Drug therapy -- Patient outcomes, Cancer -- Relapse -- Research, Biological sciences, Health
Abstract

Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms. Newly diagnosed MM patients (41), who either failed to respond or experienced early relapse after a bortezomib-containing induction regimen, were enrolled to evaluate the safety and efficacy of a daratumumab, carfilzomib, lenalidomide and dexamethasone combination. The primary clinical endpoint was safety and tolerability. Secondary endpoints included overall response rate, progression-free survival and overall survival. Treatment was safe and well tolerated; deep and durable responses were achieved. In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular pathways of resistance, including hypoxia tolerance, protein folding and mitochondria respiration, which generalized to larger clinical cohorts (CoMMpass). We found peptidylprolyl isomerase A (PPIA), a central enzyme in the protein-folding response pathway, as a potential new target for resistant MM. CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with a small molecule inhibitor (ciclosporin) significantly sensitizes MM tumor cells to proteasome inhibitors. Together, our study defines a roadmap for integrating scRNA-seq in clinical trials, identifies a signature of highly resistant MM patients and discovers PPIA as a potent therapeutic target for these tumors. Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential actionable targets., Author(s): Yael C. Cohen [sup.1] [sup.2] , Mor Zada [sup.1] [sup.3] , Shuang-Yin Wang [sup.3] , Chamutal Bornstein [sup.3] , Eyal David [sup.3] , Adi Moshe [sup.3] , Baoguo Li [...]

Published
2021
Full Text
View/download PDF

15. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia

Author

Canaani, Jonathan, primary, Frisch, Avraham, additional, Pollyea, Daniel A., additional, Schwartz, Marc, additional, Aumann, Shlomzion, additional, Ganzel, Chezi, additional, Haran, Arnon, additional, Even‐Zohar, Noa Gross, additional, Shaulov, Adir, additional, Vainstein, Vladimir, additional, Moshe, Yakir, additional, Ofran, Yishai, additional, Wolach, Ofir, additional, and Nachmias, Boaz, additional

Published
2023
Full Text
View/download PDF

16. Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA

Author

Hiayev, Stephany, primary, Shacham-Shmueli, Einat, additional, Berkovitch, Matitiahu, additional, Weiss, Ilana, additional, Ashkenazi, Shai, additional, Vexberg, Michal Hirsch, additional, Hershkowitz, Rami, additional, Gorelik, Einat, additional, Mayan, Haim, additional, Steinmetz, Yehudit, additional, Yanai, Noa Berar, additional, Schlissel, Orly, additional, Azem, Muhammad, additional, Gutgold, Neriya, additional, Shulman, Katerina, additional, Divinsky, Milly, additional, Yarom, Nirit, additional, Vishkautzan, Alla, additional, Ganzel, Chezi, additional, Gatt, Moshe E, additional, Arcavi, Lidia, additional, Marom, Eli, additional, Uziely, Biatrice, additional, Zevin, Shoshana, additional, Meirow, Hadar, additional, Luxenburg, Osnat, additional, and Ainbinder, Denize, additional

Published
2023
Full Text
View/download PDF

17. Data from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Author

Diamond, Eli L., primary, Durham, Benjamin H., primary, Haroche, Julien, primary, Yao, Zhan, primary, Ma, Jing, primary, Parikh, Sameer A., primary, Wang, Zhaoming, primary, Choi, John, primary, Kim, Eunhee, primary, Cohen-Aubart, Fleur, primary, Lee, Stanley Chun-Wei, primary, Gao, Yijun, primary, Micol, Jean-Baptiste, primary, Campbell, Patrick, primary, Walsh, Michael P., primary, Sylvester, Brooke, primary, Dolgalev, Igor, primary, Aminova, Olga, primary, Heguy, Adriana, primary, Zappile, Paul, primary, Nakitandwe, Joy, primary, Ganzel, Chezi, primary, Dalton, James D., primary, Ellison, David W., primary, Estrada-Veras, Juvianee, primary, Lacouture, Mario, primary, Gahl, William A., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ross, Jeffrey S., primary, Ali, Siraj M., primary, Briggs, Samuel R., primary, Fasan, Omotayo, primary, Block, Jared, primary, Héritier, Sebastien, primary, Donadieu, Jean, primary, Solit, David B., primary, Hyman, David M., primary, Baselga, José, primary, Janku, Filip, primary, Taylor, Barry S., primary, Park, Christopher Y., primary, Amoura, Zahir, primary, Dogan, Ahmet, primary, Emile, Jean-Francois, primary, Rosen, Neal, primary, Gruber, Tanja A., primary, and Abdel-Wahab, Omar, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Methods, Figures 1 - 5, Tables 1 - 5 from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Author

Diamond, Eli L., primary, Durham, Benjamin H., primary, Haroche, Julien, primary, Yao, Zhan, primary, Ma, Jing, primary, Parikh, Sameer A., primary, Wang, Zhaoming, primary, Choi, John, primary, Kim, Eunhee, primary, Cohen-Aubart, Fleur, primary, Lee, Stanley Chun-Wei, primary, Gao, Yijun, primary, Micol, Jean-Baptiste, primary, Campbell, Patrick, primary, Walsh, Michael P., primary, Sylvester, Brooke, primary, Dolgalev, Igor, primary, Aminova, Olga, primary, Heguy, Adriana, primary, Zappile, Paul, primary, Nakitandwe, Joy, primary, Ganzel, Chezi, primary, Dalton, James D., primary, Ellison, David W., primary, Estrada-Veras, Juvianee, primary, Lacouture, Mario, primary, Gahl, William A., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ross, Jeffrey S., primary, Ali, Siraj M., primary, Briggs, Samuel R., primary, Fasan, Omotayo, primary, Block, Jared, primary, Héritier, Sebastien, primary, Donadieu, Jean, primary, Solit, David B., primary, Hyman, David M., primary, Baselga, José, primary, Janku, Filip, primary, Taylor, Barry S., primary, Park, Christopher Y., primary, Amoura, Zahir, primary, Dogan, Ahmet, primary, Emile, Jean-Francois, primary, Rosen, Neal, primary, Gruber, Tanja A., primary, and Abdel-Wahab, Omar, primary

Published
2023
Full Text
View/download PDF

19. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

Author

Guryanova, Olga A, Shank, Kaitlyn, Spitzer, Barbara, Luciani, Luisa, Koche, Richard P, Garrett-Bakelman, Francine E, Ganzel, Chezi, Durham, Benjamin H, Mohanty, Abhinita, Hoermann, Gregor, Rivera, Sharon A, Chramiec, Alan G, Pronier, Elodie, Bastian, Lennart, Keller, Matthew D, Tovbin, Daniel, Loizou, Evangelia, Weinstein, Abby R, Gonzalez, Adriana Rodriguez, Lieu, Yen K, Rowe, Jacob M, Pastore, Friederike, McKenney, Anna Sophia, Krivtsov, Andrei V, Sperr, Wolfgang R, Cross, Justin R, Mason, Christopher E, Tallman, Martin S, Arcila, Maria E, Abdel-Wahab, Omar, Armstrong, Scott A, Kubicek, Stefan, Staber, Philipp B, Gönen, Mithat, Paietta, Elisabeth M, Melnick, Ari M, Nimer, Stephen D, Mukherjee, Siddhartha, and Levine, Ross L

Subjects
Anthracyclines -- Dosage and administration, Methyltransferases -- Research, Gene mutation -- Research, Drug resistance -- Research, Acute myelocytic leukemia -- Genetic aspects -- Drug therapy -- Research, Biological sciences, Health
Abstract

Author(s): Olga A Guryanova [1]; Kaitlyn Shank [1]; Barbara Spitzer [2]; Luisa Luciani [3]; Richard P Koche [4, 5]; Francine E Garrett-Bakelman [6]; Chezi Ganzel [7]; Benjamin H Durham [1]; [...]

Published
2016
Full Text
View/download PDF

20. Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Author

Stemer, Galia, primary, Wolach, Ofir, additional, Levi, Itai, additional, Nachmias, Boaz, additional, Tavor, Sigal, additional, Canaani, Jonathan, additional, Ofran, Yishai, additional, Ganzel, Chezi, additional, Zuckerman, Tsila, additional, Okasha, Doaa, additional, Hellmann, Ilana, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Cohen, Raanan, additional, Berelovich, Jenia, additional, Ofek, Keren, additional, Rivlin, Noa, additional, Frankel, Neta, additional, Grunspan, Moshe, additional, and Moshe, Yakir, additional

Published
2022
Full Text
View/download PDF

22. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Author

Cohen, Yael C, primary, Gatt, Moshe E, additional, Luttwak, Efrat, additional, Lavi, Noa, additional, Ganzel, Chezi, additional, Chubar, Evgeni, additional, Rouvio, Ory, additional, Vaxman, Iuliana, additional, Pasvolsky, Oren, additional, Ballan, Mouna, additional, Tadmor, Tamar, additional, Nemets, Anatoly, additional, Jarchowsky, Osnat, additional, Shvetz, Olga, additional, Shpilberg, Ofer, additional, Dally, Najib, additional, Leiba, Merav, additional, Weiner, Assaf, additional, Zada, Mor, additional, Wang, Shuang-Yin, additional, Gur, Chamutal, additional, Lowenton-Spier, Noa, additional, Goor-Porges, Liron, additional, Amit, Ido, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

23. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Author

Vassilakopoulos, Theodoros P., primary, Panitsas, Fotios, additional, Mellios, Zois, additional, Apostolidis, John, additional, Piperidou, Alexia, additional, Michael, Michalis D, additional, Gurion, Ronit, additional, Akay, Meltem, additional, Hatzimichael, Eleftheria, additional, Karakatsanis, Stamatis J., additional, Dimou, Maria, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Giatra, Chara, additional, Kanellias, Nikolaos, additional, Sayyed, Ayman, additional, Tadmor, Tamar, additional, Kaynar, Leylagul, additional, Zektser, Miri, additional, Symeonidis, Argiris, additional, Atalar, SC, additional, Verrou, Evgenia, additional, Gutwein, Odit, additional, Ganzel, Chezi, additional, Karianakis, Giorgos, additional, Isenberg, Jonathan, additional, Gainaru, Gabriela, additional, Triantafyllou, Theodora, additional, Vrakidou, Efimia, additional, Palassopoulou, Maria, additional, Ozgur, Mehmet, additional, Paydas, Semra, additional, Tsirigotis, Panagiotis, additional, Tsirogianni, Maria, additional, Tuglular, Tulin, additional, Chatzidimitriou, Chrysovalantou, additional, Kotsopoulou, Maria, additional, Terpos, Evangelos, additional, Zikos, Panagiotis, additional, Koumarianou, Argyro, additional, Poziopoulos, Christos, additional, Boutsis, Dimitrios, additional, Gafter-Gvili, Anat, additional, Karmiris, Themistoklis, additional, Angelopoulou, Maria K., additional, Bakiri Papaioannou, Maria, additional, Pangalis, Gerassimos, additional, Panayiotidis, Panayiotis, additional, Ferhanoglu, Burhan, additional, Horowitz, Netanel A., additional, and Papageorgiou, Sotirios, additional

Published
2022
Full Text
View/download PDF

24. Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Author

Ganzel, Chezi, primary, Moshe, Yakir, additional, Levi, Itai, additional, Nachmias, Boaz, additional, Tavor, Sigal, additional, Canaani, Jonathan, additional, Zuckerman, Tsila, additional, Okasha, Doaa, additional, Hellmann, Ilana, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Stemer, Galia, additional, Cohen, Raanan, additional, Berelovich, Jenia, additional, Rivlin, Noa, additional, Frankel, Neta, additional, Grunspan, Moshe, additional, Ofek, Keren, additional, Ofran, Yishai, additional, and Wolach, Ofir, additional

Published
2022
Full Text
View/download PDF

25. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Author

Cohen, Yael C, primary, Shragai, Tamir, additional, Lavi, Noa, additional, Vaxman, Iuliana, additional, Chubar, Evgeni, additional, Gatt, Moshe E, additional, Ganzel, Chezi, additional, Magen, Hila, additional, Luttwak, Efrat, additional, Lowenton-Spier, Noa, additional, Gez-Aaronson, Liron, additional, Melamed, Natan, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

27. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group

Author

Ganzel, Chezi, primary, Trestman, Svetlana, additional, Levi, Shai, additional, Gatt, Moshe E., additional, Lavi, Noa, additional, Vaxman, Iuliana, additional, Rouvio, Ory, additional, Magen, Hila, additional, Lebel, Eyal, additional, Horowitz, Netanel A., additional, Leiba, Merav, additional, Tadmor, Tamar, additional, Herzog Tzarfati, Katrin, additional, Surio, Celia, additional, Yeganeh, Shay, additional, Dally, Nagib, additional, Avivi, Irit, additional, and Cohen, Yael C., additional

Published
2022
Full Text
View/download PDF

30. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

Author

Shragai, Tamir, primary, Magen, Hila, additional, Lavi, Noa, additional, Gatt, Moshe, additional, Trestman, Svetlana, additional, Zektser, Miri, additional, Ganzel, Chezi, additional, Jarchowsky, Osant, additional, Berger, Tamar, additional, Tadmor, Tamar, additional, Leiba, Merav, additional, Hertzog-Zarfaty, Katrin, additional, Horowitz, Netanel, additional, Shapira, Michael, additional, Varssano, David, additional, Berger, Yoav, additional, Frenkel, Shahar, additional, Krauthammer, Mark, additional, Avivi, Irit, additional, Luttwak, Efrat, additional, and Cohen, Yael, additional

Published
2022
Full Text
View/download PDF

36. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.

Author

Shragai, Tamir, Magen, Hila, Lavi, Noa, Gatt, Moshe, Trestman, Svetlana, Zektser, Miri, Ganzel, Chezi, Jarchowsky, Osnat, Berger, Tamar, Tadmor, Tamar, Leiba, Merav, Hertzog‐Tzarfaty, Katrin, Horowitz, Netanel, Shapira, Michael, Varssano, David, Berger, Yoav, Frenkel, Shahar, Krauthammer, Mark, Avivi, Irit, and Luttwak, Efrat

Subjects
MULTIPLE myeloma, OCULAR toxicology, PROGRESSION-free survival, RETROSPECTIVE studies, OVERALL survival
Abstract

Summary: Belantamab mafodotin, an immuno‐conjugate targeting B‐cell maturation antigen, showed single‐agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real‐world data and long‐term follow‐up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One‐hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow‐up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression‐free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real‐world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Author

Ganzel, Chezi, primary, Roopcharan, Kevin, additional, Sun, Zhuoxin, additional, Rowe, Jacob M., additional, Fernandez, Hugo F, additional, Paietta, Elisabeth M., additional, Luger, Selina M., additional, Lazarus, Hillard M, additional, Cripe, Larry D, additional, Douer, Dan, additional, Wiernik, Peter H., additional, Tallman, Martin S., additional, and Litzow, Mark R., additional

Published
2021
Full Text
View/download PDF

38. Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Author

Altman, Jessica K., primary, Koprivnikar, Jamie, additional, McCloskey, James K, additional, Kota, Vamsi, additional, Keng, Michael, additional, Bixby, Dale L., additional, Frankfurt, Olga, additional, Emadi, Ashkan, additional, Zuckerman, Tsila, additional, Burch, Micah M., additional, Levy, Moshe Y., additional, Luger, Selina M., additional, Bhatnagar, Bhavana, additional, Wolach, Ofir, additional, Ganzel, Chezi, additional, Percival, Mary-Beth M., additional, Roboz, Gail J., additional, Craig, Michael, additional, Levi, Itai, additional, Gourevitch, Anna, additional, Flaishon, Liat, additional, Cohen, Darrel P., additional, Tessler, Shoshi, additional, Blumberg, Chen, additional, Gengrinovitch, Stela, additional, Ben Yakar, Ruth, additional, and Rowe, Jacob M., additional

Published
2021
Full Text
View/download PDF

43. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Author

Cohen, Yael C., Shragai, Tamir, Lavi, Noa, Vaxman, Iuliana, Chubar, Evgeni, Gatt, Moshe E, Ganzel, Chezi, Magen, Hila, Luttwak, Efrat, Mittelman, Moshe, Tzoran, Inna, Vainstein, Vladimir, Lowenton-Spier, Noa, Melamed, Natan, Krayzler, Ella, Pereg, Ilana, and Avivi Mazza, Irit

Published
2023
Full Text
View/download PDF

44. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Olszewski, Adam J, Eradat, Herbert, Avigdor, Abraham, Horowitz, Netanel A., Babu, Sunil, Levi, Itai, McKinney, Matthew, Lee, Seung Tae, Bergua Burgues, Juan Miguel, Rodriguez Izquierdo, Antonia, Bastos-Oreiro, Mariana, Ganzel, Chezi, Kim, Tae Min, Jeon, Youngwoo, Taszner, Michal, Narkhede, Mayur, Kim, Won Seog, Shin, Ho-Jin, Lavie, David, Woszczyk, Dariusz, Dunshee, Diana, Kapp, Amy V., Zhou, Mingzhu, Batlevi, Connie Lee, Ead, Wahib, Sellam, Gila, and Jurczak, Wojciech

Published
2023
Full Text
View/download PDF

47. Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

Author

Altman, Jessica K., primary, Koprivnikar, Jamie, additional, McCloskey, James K., additional, Kota, Vamsi, additional, Frankfurt, Olga, additional, Emadi, Ashkan, additional, Bixby, Dale, additional, Burch, Micah, additional, Levy, Moshe Yair, additional, Luger, Selina, additional, Zuckerman, Tsila, additional, Bhatnagar, Bhavana, additional, Wolach, Ofir, additional, Ganzel, Chezi, additional, Levi, Itai, additional, Gourevitch, Anna, additional, Ben Yakar, Ruth, additional, Tessler, Shoshi, additional, Flaishon, Liat, additional, and Rowe, Jacob, additional

Published
2021
Full Text
View/download PDF

48. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

Author

Apel, Arie, primary, Moshe, Yakir, additional, Ofran, Yishai, additional, Gural, Alexander, additional, Wolach, Ofir, additional, Ganzel, Chezi, additional, Canaani, Jonathan, additional, Zektser, Miri, additional, Duek, Adrian, additional, Stemer, Galia, additional, Hellman, Ilana, additional, Basood, May, additional, Frisch, Avraham, additional, Leibovitch, Chiya, additional, and Koren‐Michowitz, Maya, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results